Race Oncology Ltd (ASX:RAC, OTC:RAONF) will host a special investor lunch briefing in Hong Kong on October 14, 2025, outlining its clinical development strategy and recent milestones.
Executive chairman Dr Pete Smith and managing director and CEO Dr Daniel Tillett will provide an update on the company’s pipeline, including the opening of new clinical trial sites in Hong Kong – a step seen as pivotal to the global expansion of Race’s cancer therapy program. Attendees will also have the opportunity to engage directly with management in a Q&A session over lunch.
The event will take place at the Grand Hyatt Hotel’s Library Room, beginning at 12:30 pm Hong Kong time. Attendance is limited, with RSVPs required by September 26, 2025.
Race’s lead drug candidate, RCDS1 (E,E-bisantrene), is being advanced in proprietary formulation RC220 for solid tumours and acute myeloid leukaemia. The company’s development efforts centre on combinations with anthracycline to deliver cardioprotection alongside anticancer efficacy.
Race has established collaborations with leading institutions including Astex, MD Anderson, Sheba City of Health, and the University of Newcastle, and continues to explore partnerships and potential transactions to accelerate access to RC220 for cancer patients worldwide.
Event Details
- RSVP: Places are strictly limited. Please RSVP by September 26, 2025 to: jane.lowe@irdepartment.com.au